Effect of capecitabine on breast cancer patients with different estrogen receptor status
Bangladesh Journal of Pharmacology, 2020 This meta-analysis is to compare the efficacy of capecitabine versus non-capecitabine chemotherapy on breast cancer patients with different estrogen receptor (ER) status.
Gang Xu +5 more
doaj +1 more source
Cancer Treatment and Research Communications, 2023 Background: The combination of endocrine treatment with cycline-dependent-kinase 4/6 inhibitor is the new standard of treatment in hormone receptor-positive HER2 negative metastatic breast cancer.
L. Bender +6 more
doaj +1 more source
Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor. [PDF]
, 2012 Pancreatic neuroendocrine tumors (PNETs) are relatively rare tumors that arise in the endocrine cells of the pancreas. Historically, somatostatin analogues have been used in this disease primarily for symptom control and, to a limited extent, disease ...
Devata, Sumana, Kim, Edward J
core +2 more sources
Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?
Oncology Reviews, 2011 Fluorouracil (5-FU) remains the most widely used agent for colorectal cancer. Capecitabine is a rationally designed 5-FU pro-drug developed to mimic the continuous infusion of 5-FU while avoiding complications and inconvenience of intravenous ...
Lakshmi Chintala +3 more
doaj +1 more source
A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract [PDF]
, 2016 Background: Advanced biliary tract carcinomas are associated with a poor prognosis, and palliative chemotherapy has only modest benefit. This multi-centre phase II study was conducted to determine the efficacy of capecitabine in combination with ...
E. Soulis +10 more
core +1 more source
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation [PDF]
, 2003 Objectives: To evaluate the clinical and costeffectiveness of capecitabine and tegafur with uracil (UFT/LV) as first-line treatments for patients with metastatic colorectal cancer, as compared with 5- fluorouracil/folinic acid (5-FU/FA) regimens.
Brewer, N. +3 more
core +1 more source
The Impact of Capecitabine and Combined Training on BRCA1 Gene Expression in Breast Cancer Induction [PDF]
Journal of Basic Research in Medical Sciences, 2023 Introduction: This study explores the combined effects of concurrent training and capecitabine consumption on breast cancer prevention and therapy, focusing on the modulation of BRCA1 gene expression.
Masoud Shokuhi Niya +3 more
doaj
Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials. [PDF]
PLoS ONE, 2016 Capecitabine has been investigated in early breast cancer in several studies, but it was undefined that whether it could improve survival. To investigate whether the addition of capecitabine affected survival in patients with early breast cancer, a meta ...
Ze-Chun Zhang +3 more
doaj +1 more source
Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. [PDF]
, 2013 The widespread use of trastuzumab in the past decade has led to a significant and measureable improvement in the survival of patients with human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer, and in many ways has redefined the ...
Chien, A Jo, Rugo, Hope S
core +1 more source
Therapeutic Advances in Medical Oncology, 2019 Background: Capecitabine is generally dosed based on body surface area (BSA). This dosing strategy has several limitations; however, evidence for alternative strategies is lacking.
Femke M. de Man +10 more
doaj +1 more source